"Low-risk" myelodysplastic neoplasm (MDS): Time for a name change?
作者信息
Burke Shoshana, Hibbs Stephen P
机构信息
Barts Cancer Institute Queen Mary University of London London UK.
Wolfson Institute of Population Health Queen Mary University of London London UK.
出版信息
Hemasphere. 2025 Jan 7;9(1):e70066. doi: 10.1002/hem3.70066. eCollection 2025 Jan.
Abstract
摘要
相似文献
1
"Low-risk" myelodysplastic neoplasm (MDS): Time for a name change?“低风险”骨髓增生异常肿瘤（MDS）：是时候改名了吗？
Hemasphere. 2025 Jan 7;9(1):e70066. doi: 10.1002/hem3.70066. eCollection 2025 Jan.
2
[New insights into the nature and classification of myelodysplastic neopmasm].
Zhonghua Yi Xue Za Zhi. 2024 Dec 10;104(46):4193-4196. doi: 10.3760/cma.j.cn112137-20240718-01647.
3
The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.髓系基因突变panel 在骨髓增生异常综合征和骨髓增生异常/骨髓增殖性肿瘤诊断中的应用。
Int J Lab Hematol. 2021 Dec;43(6):1501-1509. doi: 10.1111/ijlh.13659. Epub 2021 Jul 16.
4
Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.骨髓增生异常综合征和骨髓增生异常/骨髓增殖性肿瘤的进展、转化和不典型表现：从 2019 年第十四届欧洲骨髓工作小组课程中获得的经验教训。
Ann Hematol. 2021 Jan;100(1):117-133. doi: 10.1007/s00277-020-04307-9. Epub 2020 Oct 31.
5
Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.骨髓增生异常/骨髓增殖性肿瘤的基因组景观：一项多中心研究。
Int J Mol Sci. 2024 Sep 23;25(18):10214. doi: 10.3390/ijms251810214.
6
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?骨髓增生异常/骨髓增殖性肿瘤，不能分类（MDS/MPN-U）：不仅仅是一个“包罗万象”的术语？
Best Pract Res Clin Haematol. 2020 Jun;33(2):101132. doi: 10.1016/j.beha.2019.101132. Epub 2019 Dec 6.
7
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.SOHO 最新进展及下一步问题：高危骨髓增生异常综合征的更新
Clin Lymphoma Myeloma Leuk. 2024 Sep;24(9):573-582. doi: 10.1016/j.clml.2024.03.006. Epub 2024 Mar 18.
8
Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.骨髓增生异常综合征或骨髓增生异常/骨髓增殖性肿瘤后继发的淋巴母细胞白血病。
Leuk Lymphoma. 2019 Dec;60(12):2993-3001. doi: 10.1080/10428194.2019.1605509. Epub 2019 Apr 24.
9
The Ataxia-telangiectasia mutated (ATM) is the most important gene for repairing the DNA in Myelodysplastic Neoplasm.共济失调毛细血管扩张症突变基因（ATM）是骨髓增生异常综合征中修复DNA最重要的基因。
DNA Repair (Amst). 2025 Feb;146:103803. doi: 10.1016/j.dnarep.2024.103803. Epub 2025 Jan 17.
10
[Analysis of the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome with blastomycosis and survival comparison of different subtypes after the WHO 2022 reclassification].[骨髓增生异常综合征合并母细胞增多症患者异基因造血干细胞移植的疗效及预后因素分析以及2022年世界卫生组织重新分类后不同亚型的生存比较]
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):445-452. doi: 10.3760/cma.j.cn121090-20231109-00258.
引用本文的文献
1
Low-risk MDS-A spotlight on precision medicine for mutated patients.低风险骨髓增生异常综合征——聚焦于针对突变患者的精准医学
Hemasphere. 2025 Mar 21;9(3):e70103. doi: 10.1002/hem3.70103. eCollection 2025 Mar.
本文引用的文献
1
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.2022 年世界卫生组织分类与骨髓增生异常综合征/肿瘤国际共识分类的比较。
Blood Cancer J. 2024 Apr 9;14(1):57. doi: 10.1038/s41408-024-01031-9.
2
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
3
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
4
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
5
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
6
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.英国血液学学会成人骨髓增生异常综合征管理指南
Br J Haematol. 2021 Jul;194(2):267-281. doi: 10.1111/bjh.17612. Epub 2021 Jun 27.
7
Outpatient transfusions for myelodysplastic syndromes.骨髓增生异常综合征的门诊输血治疗。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):167-174. doi: 10.1182/hematology.2020000103.
8
Therapy for lower-risk MDS.低危 MDS 的治疗。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):426-433. doi: 10.1182/hematology.2020000127.
9
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes.用于低风险骨髓增生异常综合征的患者报告结局的内容效度。
J Patient Rep Outcomes. 2020 Aug 26;4(1):69. doi: 10.1186/s41687-020-00235-4.
10
Stability and change in disease prestige: A comparative analysis of three surveys spanning a quarter of a century.疾病声望的稳定性与变化：对跨越四分之一个世纪的三项调查的比较分析。
Soc Sci Med. 2017 May;180:45-51. doi: 10.1016/j.socscimed.2017.03.020. Epub 2017 Mar 14.
Zotero 插件